Xeloda, Capecitabine

Xeloda, Capecitabine Newswire

Comprehensive Real-Time News Feed for Xeloda, Capecitabine (generic).

Results 1 - 20 of 107 in Xeloda, Capecitabine (generic)

  1. No Fingerprints? After Chemo, This 65-Year-Old Woman Could Be A Stealthy ThiefRead the original story w/Photo

    15 hrs ago | Medical Daily

    Trying to perform a transaction at her bank, a 65-year-old Mexican woman was unceremoniously turned down. Disbelieving, she tried again; after all, she knew she had enough money in her account.

    Comment?

  2. Rare side effect erased woman's fingerprintsRead the original story w/Photo

    Thursday | WTSP-TV Saint Petersburg

    A 65-year-old breast cancer patient ran into an unexpected problem with her bank: She was denied a transaction because her fingerprints had Rare side effect erased woman's fingerprints A 65-year-old breast cancer patient ran into an unexpected problem with her bank: She was denied a transaction because her fingerprints had Check out this story on wtsp.com: http://on.wtsp.com/1yy4uT2 Doctors say a 65-year-old woman's fingerprints virtually disappeared as a result of a rare side effect of chemotherapy. A 65-year-old breast cancer patient ran into an unexpected problem with her bank: She was denied a transaction because her fingerprints had disappeared.

    Comment?

  3. Bizarre Cancer Drug Side Effect: Fingerprints DisappearRead the original story w/Photo

    Thursday | News Max

    A 65-year-old breast cancer patient ran into an unexpected problem with her bank: She was denied a transaction because her fingerprints had disappeared. Reporting in the April 16 issue of the New England Journal of Medicine , doctors in Mexico said the woman's unusual case was due to the effects of chemotherapy for an advanced breast cancer that had spread to the lungs.

    Comment?

  4. The woman whose fingerprints were ERASED: Cancer patient discovers...Read the original story w/Photo

    Thursday | Daily Mail

    Capecitabine causes hand-foot syndrome, where patient's experience redness, swelling, blistering and peeling of skin on the hands and feet A cancer patient discovered her fingerprints had disappeared when she was denied authorisation to perform a banking transaction because her prints were unrecognisable. An investigation of her case, to determine how her fingerprints had disappeared, led doctors to conclude a common cancer drug, capecitabine was to blame.

    Comment?

  5. Chemo for Breast Cancer Erases Woman's FingerprintsRead the original story w/Photo

    Wednesday | HON

    A 65-year-old breast cancer patient ran into an unexpected problem with her bank: She was denied a transaction because her fingerprints had disappeared. Reporting in the April 16 issue of the New England Journal of Medicine , doctors in Mexico said the woman's unusual case was due to the effects of chemotherapy for an advanced breast cancer that had spread to the lungs.

    Comment?

  6. "Colorectal Cancer Therapeutics in Major Developed Markets to 2020"...Read the original story

    Wednesday | PR-inside.com

    GBI Research, the leading business intelligence provider, has released its latest research, "Colorectal Cancer Therapeutics in Major Developed Markets to 2020 - ", which provides in-depth analysis of the Colorectal Cancer therapeutics market in the eight major geographies of the US, Canada, the UK, France, Germany, Spain, Italy and Japan. The report provides an estimation of the market size for 2013, along with market forecast until 2020.

    Comment?

  7. Neratinib Plus Capecitabine Shows Promise in HER2-Positive Metastatic Breast Cancer StudyRead the original story

    Tuesday Apr 14 | PressReleasePoint

    A small, stage I/II study found that giving the anti-cancer medicines neratinib and capecitabine at the same time may help people with HER2-positive metastatic breast cancer that is no longer responding to standard treatment. Breast cancer is HER2-positive when a tumor grows because too many human epidermal growth factor receptor 2 proteins cause cells to multiply more quickly than normal.

    Comment?

  8. Colorectal cancer treatment market forecast to be worth US$9.4Bn by 2020Read the original story w/Photo

    Monday Apr 13 | PR-inside.com

    New analysis states that this growth, which will occur across eight major developed countries, namely the US, UK, France, Germany, Spain, Italy, Japan and Canada, will be limited by the patent expirations of Avastin and Erbitux during the forecast period, which will prompt the uptake of lower-priced biosimilar versions of these drugs. Despite its patent expiration, Avastin is expected to retain its market-leading position in the global CRC space through to 2020.

    Comment?

  9. Oxaliplatin toxicity presenting as a liver nodule - case reportRead the original story

    Friday Apr 10 | BioMed Central

    This is an Open Access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver applies to the data made available in this article, unless otherwise stated.

    Comment?

  10. Celldex' Phase 2 EMERGE Study Of Glembatumumab Vedotin In Metastatic Breast Cancer Published In /iRead the original story

    Monday Apr 6 | BioSpace

    Celldex Therapeutics, Inc. today announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology . The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB .

    Comment?

  11. Colorectal Cancer Therapeutics in Major Developed Markets to 2020 -...Read the original story

    Wednesday Apr 1 | Sys-Con Media

    The report provides an estimation of the market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth pipeline analysis, and deal analysis.

    Comment?

  12. Teva: A Pharmaceutical Gem From IsraelRead the original story w/Photo

    Monday Mar 30 | Seeking Alpha

    Did you know that in the United States approximately 18 prescriptions are filled with Teva Pharmaceuticals' products every second? Also, approximately 1 out of every 7 prescriptions in the country is filled with a Teva product? The list goes on. Teva, Israel's largest pharmaceutical company, employs over 46,000 people worldwide.

    Comment?

  13. GenSpera Contends In The Prodrug Space, Reaching Phase 3Read the original story w/Photo

    Monday Mar 30 | Seeking Alpha

    Prodrugs are primarily used in order to allow an active molecule to arrive intact to a desired point without being metabolized too early and losing effectiveness. GenSpera has completed phase 2 for a different kind of prodrug called Mipsagargin - the inactive version masks a cytotoxic poison metabolized and activated only within solid tumor cancers.

    Comment?

  14. "Fresenius Kabi Oncology Limited (FKONCO) - Financial and Strategic SWOT Analysis Review" PublishedRead the original story

    Sunday Mar 29 | PR-inside.com

    Fresenius Kabi Oncology Limited is a pharmaceutical company. The company develops and manufactures oncology drugs.

    Comment?

  15. Canadian Pharmacy Announces the Generic Cancer Drugs ProgramRead the original story w/Photo

    Thursday Mar 26 | 24-7 Press Release

    NationDrugs.com announces that cancer patients now have more access to more affordable medications through its International Generics Program MONTREAL, QC, March 27, 2015 /24-7PressRelease/ -- NationDrugs.com the premier Canadian pharmacy intermediary since 2002 highlights the need to help cancer patients find access to more affordable cancer medications. The Wall Street Journal featured an article in February 2015 about Hagop Kantarjian discussing his concern for the affordability of cancer drugs.

    Comment?

  16. Skip Peregrine Pharmaceuticals For 2015Read the original story w/Photo

    Wednesday Mar 25 | Seeking Alpha

    Peregrine Pharmaceuticals is a small biopharmaceutical company focused on a new class of antibodies that bind to phosphatidylserine . PS is externalized on the outer membrane of tumor cells and vasculature, but is normally localized inside healthy blood vessel cells, making PS a specific target for anticancer therapies.

    Comment?

  17. Rectal Cancer Therapeutic Pipeline Assessment and Review H1 2015 Market Research ReportRead the original story

    Tuesday Mar 24 | Sys-Con Media

    RnRMarketResearch.com adds "Rectal Cancer - Pipeline Review, H1 2015" therapeutic market research report of 106 pages with latest updates, data and information to its online business intelligence library. The report " Rectal Cancer - Pipeline Review, H1 2015 " provides comprehensive information on the therapeutic development for Rectal Cancer , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action , route of administration and molecule type, along with latest updates, and featured news and press releases.

    Comment?

  18. "Teva Pharmaceuticals Europe B.V. - Strategic SWOT Analysis Review"...Read the original story

    Thursday Mar 19 | PR-inside.com

    It provides generic and branded medicines. The company develops and produces drugs that are used to address patients' needs.

    Comment?

  19. UPDATE 1-Nektar drug fails late-stage study in breast cancer patientsRead the original story

    Mar 17, 2015 | Reuters

    Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study. The drug, NKTR-102, provided a 2.1 month improvement in median overall survival over patients on chemotherapy in the trial, but the effect was not statistically significant, the company said.

    Comment?

  20. Nektar Therapeutics Cancer Drug Improves Survival But Misses Primary Endpoint, As Watchers WorryRead the original story w/Photo

    Mar 17, 2015 | BioSpace

    March 17, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor San Francisco-Booming Nektar Therapeutics had mixed news Tuesday, after it reported solid topline results from its Phase III trial of its experimental breast cancer drugs, saying it improved survival in patients studied by a little over two months. But the study missed its primary endpoint, throwing into doubt just how solid those results could be in the long term.

    Comment?